Found 2029 results for "cancer"
Computational pathology is approaching a clinical inflection point, and the bottleneck is no longer algorithmic accuracy but practical deployability. A…
Oral health is rarely the first concern raised in cannabis policy discussions, yet mounting evidence suggests the mouth may be one of the most consistent…
Selecting the right immunotherapy for non-small cell lung cancer patients has long been an educated guess dressed in statistical clothing. PD-L1 expression…
For the roughly 30,000 Americans living with Huntington's disease and the hundreds of thousands at genetic risk, the absence of disease-modifying therapies…
For patients who develop diabetes after pancreatic cancer surgery, glucose management is among the most dangerous and demanding clinical challenges in…
For patients with rectal cancer, the prospect of avoiding total surgical removal of the rectum — and the lifelong functional consequences that follow — has…
Children whose immune systems are compromised by cancer treatment, organ transplantation, or biologic therapies occupy a precarious position in respiratory…
Triple-negative breast cancer remains one of oncology's most stubborn challenges precisely because it lacks the targetable receptors that make other breast…
Triple-negative breast cancer carries one of oncology's bleakest prognoses precisely because it lacks the hormone receptor and HER2 targets that modern…
One of the most closely watched questions in oncology immunotherapy has been whether blocking TIGIT — a second immune checkpoint — on top of PD-L1 inhibition…
Immunotherapy has fundamentally redrawn the oncology treatment map over the past decade, yet the specific promise of therapeutic cancer vaccines — designed to…
Understanding how genetic information is read and translated may be about to undergo a significant conceptual upgrade. Beyond the familiar sequence of A, U…
Postmenopausal osteoporosis affects hundreds of millions of women worldwide, yet current therapies often carry long-term risks or lose efficacy over time. A…
For the roughly 1–2% of non-small cell lung cancer patients whose tumors are driven by ROS1 fusions, disease progression into the brain and acquired…
For the roughly 15% of Western and up to 50% of Asian NSCLC patients whose tumors harbor EGFR mutations, treatment decisions have undergone a quiet revolution…
As antibody-drug conjugates reshape the oncology landscape, a critical gap remains between clinical trial populations and the patients actually receiving…
One of the fundamental constraints in modern medicine is that therapeutic antibodies — among the most precise biological tools available — cannot naturally…
Most Alzheimer's research has focused on amyloid plaques, tau tangles, and neuroinflammation — but a fundamental layer of the disease's molecular machinery…
Small-cell lung cancer carries one of oncology's bleakest prognoses precisely because it responds well to initial platinum-based chemotherapy, then rebounds…
Predicting which lung cancer patients will respond to immunotherapy remains one of oncology's most consequential unsolved challenges — a wrong call means…